Bifogade filer
Kurs
+1,69%
Likviditet
1,20 MSEK
Kalender
Est. tid* | ||
2026-02-05 | 08:30 | Bokslutskommuniké 2025 |
2025-11-13 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-08-21 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-05-30 | N/A | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2025-05-28 | N/A | Årsstämma |
2025-05-15 | 08:30 | Kvartalsrapport 2025-Q1 |
2025-02-06 | - | Bokslutskommuniké 2024 |
2024-11-14 | - | Kvartalsrapport 2024-Q3 |
2024-10-30 | - | Split EXPRS2 40:1 |
2024-08-15 | - | Kvartalsrapport 2024-Q2 |
2024-06-07 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2024-06-05 | - | Årsstämma |
2024-05-16 | - | Kvartalsrapport 2024-Q1 |
2024-02-08 | - | Bokslutskommuniké 2023 |
2023-11-16 | - | Kvartalsrapport 2023-Q3 |
2023-08-17 | - | Kvartalsrapport 2023-Q2 |
2023-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2023-05-24 | - | Årsstämma |
2023-05-16 | - | Kvartalsrapport 2023-Q1 |
2023-03-23 | - | Extra Bolagsstämma 2023 |
2023-02-09 | - | Bokslutskommuniké 2022 |
2022-11-17 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-31 | - | Kvartalsrapport 2022-Q1 |
2022-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2022-05-25 | - | Årsstämma |
2022-02-24 | - | Bokslutskommuniké 2021 |
2021-11-18 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2021-05-26 | - | Årsstämma |
2021-05-19 | - | Kvartalsrapport 2021-Q1 |
2021-02-25 | - | Bokslutskommuniké 2020 |
2020-11-19 | - | Kvartalsrapport 2020-Q3 |
2020-09-23 | - | Extra Bolagsstämma 2020 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2020-05-26 | - | Årsstämma |
2020-05-20 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-24 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2019-05-23 | - | Årsstämma |
2019-05-16 | - | Kvartalsrapport 2019-Q1 |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-11-22 | - | Kvartalsrapport 2018-Q3 |
2018-08-24 | - | Kvartalsrapport 2018-Q2 |
2018-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2018-05-24 | - | Årsstämma |
2018-05-17 | - | Kvartalsrapport 2018-Q1 |
2018-02-07 | - | Bokslutskommuniké 2017 |
2017-11-30 | - | Kvartalsrapport 2017-Q3 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-06-01 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
2017-05-31 | - | Årsstämma |
2017-05-24 | - | Kvartalsrapport 2017-Q1 |
2017-04-19 | - | Extra Bolagsstämma 2017 |
2017-02-28 | - | Bokslutskommuniké 2016 |
2016-11-08 | - | Kvartalsrapport 2016-Q3 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, October 6, 2022 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces that Allan Rosetzsky, with immediate effect, has decided to resign from ExpreS2ion's board of directors. Hereafter the board of directors will consist of Martin Roland Jensen (Chair), Jakob Knudsen, Karin Garre, and Sara Sande.
"I have been an investor in ExpreS[2]ion since inception in 2010, and it is with great joy that I have participated in taking this unique company public in 2016 and been part of its growth journey in the recent 5-6 years. Time has come for me to resign, and I am glad that the remaining board of directors is in capable hands to take the pipeline-focused strategy forward," comments Allan Rosetzsky.
"I appreciate Allan's contribution in ExpreS[2]ion's board, and I wish Allan all the best in his continued role as business angel in other ventures. Now the rest of us in the board of directors will continue to support management in the execution of the pipeline-focused strategy that we embarked on in 2020. I believe that we have growth opportunities at hand that can grow the shareholder value in the foreseeable future," comments Martin Roland Jensen, Chairman.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com